Q3 2020 Sales Performance
Shingrix: US launch driving market expansion
Share uptake superior to recent
benchmarked biopharma launches
100
90
Shingrix
Market Share (%)
80
70
60
50
40
30
20
10
0
3
6
Months post launch
Source: Internal calculations by GSK using IQVIA database.
gsk
Significant US opportunity remains
Received at least first
dose of Shingrix
~14m1
Chronic Hep C
Relapsing MS
Potential revaccination
population
~23m2
Pulmonary fibrosis
Diabetes
Adults 50+ that receive
vaccinations
HIV
9
12
Population 50+
1. Estimated based on IQVIA TRxs launch through end of Dec 2019.
2. US Census & CDC reported immunisation rate.
3. US Census & IQVIA Patient Data Analysis (Estimated % of adults who
have received vaccinations when 50+).
4. US Census.
~67m³
~115m4
67
20View entire presentation